Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, SGLT2i, Topics Nov 18 | 2024Lilly Releases HFpEF and Lp(a) Data; Inventiva and Sagimet MASH Data at AASLD; New Abbott Manufacturing Facility; NeuroBo Name ChangePurchase Blast
$599
Posted in: Other, Topics Nov 15 | 2024Boston Pharmaceuticals Ph2a MASH Topline ResultsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Nov 14 | 2024Tirzepatide Full Surmount-1 Three-Year Results; Novo to Discontinue Human Insulin Pens; Hims & Hers Launches GLP-1RA Shortage Tracker; Skye Enrollment UpdatePurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Nov 14 | 2024New Zepbound DTC Observed; New Novo Insulin Trial; Amgen Damage Control; Lexicon, Fractyl, and Terns Q3 ‘24 Earnings; Metsera Series B Financing; G&L Oral GLP-1RA DataPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Nov 12 | 2024AZ, Altimmune, and Scholar Rock Q3 ’24 Earnings; New Ph2 Lilly Trial ObservedPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Topics Nov 11 | 2024November CHMP AgendaPurchase Blast
$599
Posted in: Glucagon, Glucose Monitoring, Insulin Delivery, Other, Topics Nov 08 | 2024Insulet, Senseonics, Akero, Skye, MannKind, and Xeris Q3 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Nov 07 | 2024Novo London, Tandem, Zealand, NewAmsterdam, Esperion, Viatris, and Dario Q3 ’24 Earnings; Altimmune Ph3 Obesity ProgramPurchase Blast
$599
Posted in: GLP-1RA, Other, SGLT2i, Topics Nov 06 | 2024AZ Initiates Dapa Combination Trial in HF; Ionis and Teva Q3 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Nov 06 | 2024Novo Q3 '24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, Other, Topics Nov 05 | 2024AZ Obesity Investor Event; Novo on 60 Minutes; Vertex Advances T1DM Cell Therapy; One Health CGM startup; New GLP-1RA Label UpdatesPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Nov 04 | 2024Viking VK2735 Ph2 Data @ ObesityWeek; SELECT Hospitalization Analysis; Novo/Ascendis Partnership for QM GLP-1RA; Skye CB1 Preclinical Data; Lexicon Preclinical Obesity Data; NeuroBo MASH UpdatesPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Nov 01 | 2024Novo Semaglutide MASH Data; Abbott GLP-1RA Adherence Study; Alnylam and Regeneron Q3 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Oct 31 | 2024Zynquista Negative Adcom Vote; Novo STEP-9 Results Published; Wegovy Removed from FDA Shortage List; Amgen, Madrigal, Biomea, Teladoc, and Amarin Q3 ’24 Earnings; BI/Gubra Discontinue NPY2 for Obesity; Inventiva Positive DMC Recommendation for Ph3 MASH TrialPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Oct 30 | 2024QW Icodec CRL Information; Beta Bionics Launches Libre 3+ Integration; O5 iOS App US Launch; Zealand Obesity TrialPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 30 | 2024Lilly Q3 ’24 Earnings CallPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Oct 29 | 2024Lexicon Faces Uphill Battle in Sota T1DM Adcom; Pfizer and Novartis Q3 ’24 Earnings; Sanofi Invests in Another Obesity Asset; MariTide T2DM Trial; Sagimet to Advance Denifanstat MASH DevelopmentPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Oct 28 | 2024Abbott and Tidepool Partnership; New Retatrutide Obesity Trial; Apple Prediabetes AppPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Oct 25 | 2024Dexcom and Sanofi Q3 ’24 Earnings; Zepbound Label UpdatePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Oct 25 | 2024Viking Q3 ’24 Earnings; Luna Initiates AID Trial; Fable Obesity Startup; Mounjaro Denmark LaunchPurchase Blast